🟡 Preliminary Evidence
A rare but serious form of heart infection caused by Candida (Candidozyma) auris is emerging as a clinical concern in hospitalised patients, according to a case series published in the International Journal of Infectious Diseases (September 2026). The finding adds to growing evidence that this multidrug-resistant fungus poses a significant threat beyond bloodstream infections and respiratory colonisation.
Key takeaways
- Candida auris can cause endocarditis—a potentially fatal inflammation of the heart’s inner lining—in hospitalised and immunocompromised patients
- The infection is difficult to diagnose and treat because the organism is resistant to multiple antifungal drugs
- Healthcare systems must improve surveillance and diagnostic capacity to detect fungal endocarditis early
- Clinical awareness among cardiologists and infectious disease specialists remains low, risking delayed diagnosis
Clinical risk profile for Candida auris endocarditis
Documented risk factors in hospitalised patients, based on published case reports
Source: International Journal of Infectious Diseases, September 2026 | GMJ News
A fungal pathogen moving beyond colonisation
Candida auris first emerged as a clinical problem in 2009 and has since spread globally, causing nosocomial outbreaks in intensive care units and long-term care facilities. The organism’s ability to survive on surfaces, resist multiple antifungal agents, and cause fatal bloodstream infections is well documented by the US Centers for Disease Control and Prevention (CDC). However, its role in endocarditis—infection of the heart valve and endocardium—remains underrecognised.
The case series published in the International Journal of Infectious Diseases by researchers including Dr. Farah A. Ebrahim and colleagues documents clinical presentations and outcomes in a cohort of hospitalised patients. The findings highlight that fungal endocarditis caused by Candida auris follows a more aggressive clinical course than bacterial forms, often leading to septic emboli and haemodynamic compromise. See more in our Clinical Updates section.
Diagnostic and therapeutic challenges
A central difficulty in managing Candida auris endocarditis is accurate and timely diagnosis. Traditional blood culture systems may fail to isolate the organism, and even when cultures are positive, speciation requires specialised matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF) or molecular testing—not available in all hospitals. According to the World Health Organization (WHO), delayed diagnosis of invasive fungal infections directly correlates with increased mortality.
Treatment options are severely constrained. The organism shows resistance to azoles (fluconazole, voriconazole) and reduced susceptibility to echinocandins (caspofungin, anidulafungin) in some strains. This leaves amphotericin B as often the only effective option, but its toxicity and the need for central line administration complicate management in critically ill patients. Surgical intervention—valve replacement—may be necessary but is high-risk in immunocompromised hosts. Healthcare systems with access to antifungal stewardship programmes report better outcomes.
Implications for global infection prevention
The emergence of Candida auris endocarditis signals a broader epidemiological shift in hospital-acquired infections. Rising rates of multidrug-resistant fungal pathogens reflect decades of antibiotic and antifungal selection pressure, combined with increasing numbers of immunocompromised patients (from cancer, transplantation, and HIV). The case series emphasises that infection control measures—including contact precautions, environmental disinfection, and accurate case detection—remain inadequate in many healthcare settings, particularly in low-income and middle-income countries.
According to the European Centre for Disease Prevention and Control (ECDC), systemic surveillance of Candida auris is limited, meaning true incidence and mortality from endocarditis are likely underestimated. Early recognition, rapid diagnostic confirmation, and coordinated antifungal therapy—guided by susceptibility testing—are essential for improving survival rates. Cardiologists and infectious disease specialists must maintain a high index of suspicion in patients with central lines, prior broad-spectrum antibiotic exposure, and new-onset fever with echocardiographic findings consistent with endocarditis.
Candida auris endocarditis represents a severe manifestation of invasive infection in hospitalised patients, with high mortality risk and limited therapeutic options due to multidrug resistance.
— Dr. Farah A. Ebrahim and colleagues, International Journal of Infectious Diseases (September 2026)
What this means
Frequently asked questions
How common is Candida auris endocarditis?
Precise incidence is unknown because systematic surveillance is limited globally. The case series in the International Journal of Infectious Diseases documents a small but growing number of cases in hospitalised populations. The true burden is likely higher due to underdiagnosis and inconsistent reporting. Regional surveillance data from the ECDC and CDC suggest increasing detection in Europe and North America since 2020.
Can Candida auris endocarditis be cured?
Yes, but cure requires aggressive treatment: prolonged amphotericin B intravenously (the most effective antifungal available), followed by long-term oral suppression. Many cases also require surgical valve replacement. Success depends on early diagnosis, rapid antifungal therapy, and source control (removal of infected catheters, prosthetic material). Without treatment, mortality is nearly 100%. With optimal management, survival rates vary but remain substantial.
Who is at highest risk?
Patients with central venous catheters, prolonged ICU admission, recent broad-spectrum antibiotics, advanced immunosuppression (low CD4 count, chemotherapy, post-transplant), or pre-existing valve disease are at highest risk. Neonates, elderly patients, and those with diabetes are also vulnerable. The case series highlights that risk is not uniformly distributed—awareness of local epidemiology and institutional prevalence is crucial for clinical decision-making.
As antifungal resistance spreads and the global reservoir of Candida auris expands, endocarditis caused by this pathogen will likely become an increasingly important differential diagnosis in acute cardiac care. Investing in diagnostic infrastructure, clinical education, and antifungal stewardship now can prevent future mortality and morbidity. Healthcare institutions should integrate Candida auris endocarditis into their sepsis and cardiac infection protocols, ensuring that even rare infections receive rapid, evidence-based care.
Source: Endocarditis caused by Candida (Candidozyma) auris, International Journal of Infectious Diseases, September 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
